Learn
Looking for more information?
Contact our responsive and friendly client services team any time.
Current price
$0.825
▾0.01 (1.20%)
Last trade: 27/10, 12:24PM
Market cap
$1.02b
Market closed
Talk to Opthea Limited directly.
Sign up to their Investor Hub for direct access to the Opthea Limited team, ask them questions, and see personal updates.
Investor Presentations
Principal Activity
Opthea Limited (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around VEGF-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. Opthea’s product development programs are focused on developing OPT-302 for retinal eye diseases including wet Age-related Macular Degeneration and Diabetic Macular Edema (DME). OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF- C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A and has reported outcomes from an international, multi-centre, prospective, sham-controlled, double-masked, superiority study that enrolled 366 treatment-naïve patients with wet AMD. Participants in the study were randomized in a 1:1:1 ratio to receive one of the following treatment regimens administered every 4 weeks for 24 weeks: OPT-302 (0.5 mg) in combination with ranibizumab (Lucentis®) (0.5 mg); OPT-302 (2.0 mg) in combination with ranibizumab (0.5 mg); or sham in combination with ranibizumab (0.5 mg). The study met the primary endpoint demonstrating superior vision gains in participants who received OPT-302 (2.0 mg) in combination with ranibizumab on a monthly basis over 6 months. Opthea is also investigating OPT-302 in a Phase 2a clinical trial in patients with persistent, centre-involved DME. Further details on the Company’s clinical trials can be found at: www.clinicaltrials.gov, Clinical trial identifiers: NCT02543229, NCT03345082 and NCT03397264.
Address
Unit 4/650 Chapel St, South Yarra VIC 3141, Australia
Website
News
Announcements
Filter
Announcement | T+2 Movement | Date |
---|---|---|
Market Data
Day
3m
1yr
5yr
Current price
$0.825
Open price
-
Day low-high
-
Price change
Percent change
Previous close
-
Volume
-
Turnover
-
Bid price
-
Ask price
-
Market cap
-
Shares outstanding
-
Year high
-
Year low
-
Year low-high
-
Earnings per share
-
Price/earnings ratio
-
Dividend yield
-
Dividend per share
-
Franking
-
Investor Presentations
News
Sector Peers
Company | Market Cap | ||
---|---|---|---|
Support
Live Chat
Markets